Amina Wahbi*, Safi Saeed, Shareef Nada and Dalia Abuzeid
September 20, 2023
DOI : 10.56831/PSSRP-02-060
Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once weekly Semaglutide at a dose of 0.5-1.0 mg as an adjunct to lifestyle intervention has not been confirmed. Method: This is a clinical case report of a 29-year-old female, who tried weekly Semaglutide with lifestyle intervention. We conducted a baseline mental and physical health, and we did a biweekly follow up with her. This was over 6 months period starting from September 2022 until March 2023. Consent: Written informed consent has been obtained from the patient. Results: Our participant was able to lose 16.3 % of her body weight in 6 months, dropping her body weight from 74.3 kilograms to 61.2 kilograms, with a decrease in her body mass index from 29.3 to 23.9. With a significant improvement in mental and physical health, particularly, an improvement in her depression, generalized anxiety, and ADHD symptoms. Conclusion: In participants with overweight or obesity, 0.5-1.0 mg of Semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
Keywords: Obesity; Semaglutide; weight loss